At Cephalon, they never lose sight of why they are in business: to improve health and enhance the quality of the lives of patients through smart application of science.
Founded in 1987 as a biotech start-up, Cephalon have grown into one of the world’s top ten biopharmaceutical companies, with an impressive roster of first-in-class products, a deep and diverse pipeline, and annual revenues of $1.94 billion. And even though they have grown to nearly 3,000 employees in locations around the globe, they have never lost the agility and nimbleness of a start-up.
Cephalon's portfolio of innovative treatments for central nervous system disorders, pain, and cancer include eight proprietary products in the United States, along with more than 30 products internationally. Cephalon's research pipeline is focused on developing new compounds and new indications for existing products, while their business collaborations capitalize on new products and smart drug delivery technologies.
The single greatest measure of Cephalon's success will always be the countless people who benefit from our medications every day. They are true to their legacy and why they do what they do.